Usefulness of Orlistat in the treatment of severe hypertriglyceridemia.
Wierzbicki
Anthony S
AS
Department of Chemical Pathology, St. Thomas' Hospital, London, United Kingdom. Anthony.Wierzbicki@kcl.ac.uk
Reynolds
Timothy M
TM
Crook
Martin A
MA
D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D004043:Dietary Fiber / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D005260:Female; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D015228:Hypertriglyceridemia / Q000188:drug therapy*; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use; D000077403:Orlistat; D011758:Pyrroles / Q000627:therapeutic use; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D019440:Anti-Obesity Agents; D000924:Anticholesteremic Agents; D004043:Dietary Fiber; D015525:Fatty Acids, Omega-3; D006538:Heptanoic Acids; D007783:Lactones; D011758:Pyrroles; D009525:Niacin; D000077403:Orlistat; D000069059:Atorvastatin